Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial

Dugel Pravin U.; Tolentino Michael; Feiner Leonard; Kozma Petra; Leroy Annick

首页> 外文期刊>Ophthalmology >Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial

【24h】

Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial

机译：含2年的Ocriplasmin治疗包括黄斑裂孔（OASIS）在内的有症状玻璃体粘连的随机试验结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: The Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) trial was designed to evaluate the long-term efficacy and safety profile of ocriplasmin for the treatment of symptomatic vitreomacular adhesion (VMA)/vitreomacular traction, including full-thickness macular hole (FTMH).

机译：目的：治疗包括玻璃膜黄斑裂孔在内的有症状玻璃体粘连的Ocriplasmin试验旨在评估Ocriplasmin用于治疗玻璃体粘连（VMA）/玻璃体牵引（包括全层黄斑）的长期疗效和安全性孔（FTMH）。

著录项

来源
《Ophthalmology》 |2016年第10期|共16页
作者
Dugel Pravin U.; Tolentino Michael; Feiner Leonard; Kozma Petra; Leroy Annick;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词

相似文献

外文文献
中文文献
专利

1. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial [J] . Dugel Pravin U., Tolentino Michael, Feiner Leonard, Ophthalmology . 2016,第10期

机译：含2年的Ocriplasmin治疗包括黄斑裂孔（OASIS）在内的有症状玻璃体粘连的随机试验结果
2. LONG-TERM VISUAL FUNCTIONING IMPROVEMENT IS ASSOCIATED WITH RESOLUTION OF VITREOMACULAR ADHESION IN SUBJECTS WITH VITREOMACULAR TRACTION, INCLUDING MACULAR HOLE TREATED WITH INTRAVITREAL OCRIPLASMIN: RESULTS FROM THE OASIS STUDY [J] . Lescrauwaet B., Duchateau L., Verstraeten T., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：长期视觉功能改善与解决玻璃体牵引患者的玻璃体粘连有关，包括用玻璃体内卵磷脂治疗的黄斑孔：绿洲研究结果
3. ASSOCIATION BETWEEN ANATOMICAL RESOLUTION AND FUNCTIONAL OUTCOMES IN THE MIVI-TRUST STUDIES USING OCRIPLASMIN TO TREAT SYMPTOMATIC VITREOMACULAR ADHESION/VITREOMACULAR TRACTION, INCLUDING WHEN ASSOCIATED WITH MACULAR HOLE [J] . Gandorfer Arnd, Benz Matthew S., Haller Julia A., Retina . 2015,第6期

机译：使用脂蛋白治疗有症状的玻璃体黏着/玻璃体牵引，包括与黄斑孔相关的解剖学意义上的解剖分辨率和功能结果之间的关联
4. Photodynamic therapy in the treatment of age related macular degeneration. an update on currently ongoing studies with verteporfin (TAP/VIP trial) [C] . I. Barbazetto, U. Schmidt-Erfurth Conference on Lasers and Electro-Optics Europe . 2000

机译：光动力治疗治疗年龄相关性黄斑变性。有关目前与Verteporfin进行的更新（Tap / VIP试验）
5. Assessing if randomized treatment group should be included in the imputation model when imputing missing outcome data in randomized superiority clinical trials. [D] . Lyass, Asya. 2010

机译：在随机优势临床试验中估算缺失结果数据时，评估是否应将随机治疗组纳入估算模型。
6. PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION INCLUDING MACULAR HOLE (OASIS) STUDY [O] . Calvin Mein, Pravin U. Dugel, Leonard Feiner, -1

机译：患者用卵磷脂蛋白报告的视觉功能用于治疗症状性玻璃体-静脉粘连包括黄斑裂孔（OASIS）研究
7. PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY [O] . Calvin Mein, Pravin U. Dugel, Leonard Feiner, 2019

机译：患者报告的视觉功能来自OCRIPLASMIN治疗症状玻璃体粘连，包括黄斑孔（绿洲）研究

Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial

摘要

著录项

相似文献

相关主题

期刊订阅